1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Global Obstetrics Partnering 2010-2017: Deal trends, players and financials

Global Obstetrics Partnering 2010-2017: Deal trends, players and financials

  • March 2017
  • -
  • Currentpartnering
  • -
  • 200 pages

Summary

Table of Contents

Summary
Global Obstetrics Partnering 2010-2017: Deal trends, players and financials provides understanding and access to the obstetrics partnering deals and agreements entered into by the worlds leading healthcare companies

Description
Global Obstetrics Partnering 2010 to 2017 provides the full collection of Obstetrics disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.

Trends in Obstetrics partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Obstetrics partnering agreement structure
Obstetrics partnering contract documents
Top Obstetrics deals by value
Most active Obstetrics dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Obstetrics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Obstetrics deals.

The report presents financial deal terms values for Obstetrics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Obstetrics dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Obstetrics dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Obstetrics deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Obstetrics dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Obstetrics deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Obstetrics partnering deals by specific Obstetrics target announced since 2010. The chapter is organized by specific Obstetrics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Obstetrics partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Obstetrics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Obstetrics technologies and products.

Report scope
Global Obstetrics Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Obstetrics trends and structure of deals entered into by leading companies worldwide.

Global Obstetrics Partnering 2010 to 2017 includes:
- Trends in Obstetrics dealmaking in the biopharma industry since 2010
- Analysis of Obstetrics deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Obstetrics deal contract documents
- Comprehensive access to over 3500 Obstetrics deal records
- The leading Obstetrics deals by value since 2010
- Most active Obstetrics dealmakers since 2010

The report includes deals for the following indications: Analgesia in labour, Breastfeeding, Fetal abnormalities, Gestational diabetes, Hemorrhage, Hemolytic disease of the newborn, Hypertension in pregnancy, Labour induction, Nausea, Pre-eclampsia, Prenatal screening, Pregnancy, Ectopic, Hydatiform mole, Miscarriage, Termination, Preterm labour, Vomiting, plus other obstetric indications.

In Global Obstetrics Partnering 2010 to 2017, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Obstetrics Partnering 2010 to 2017 report provides comprehensive access to available deals and contract documents for over 3500 Obstetrics deals.

Analyzing actual contract agreements allows assessment of the following:
- What are the precise Obstetrics rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Global Obstetrics Partnering 2010 to 2017 provides the reader with the following key benefits:
- In-depth understanding of Obstetrics deal trends since 2010
- Access Obstetrics deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between Obstetrics partner companies
- Comprehensive access to over 750 links to actual Obstetrics deals entered into by the world’s biopharma companies
- Indepth review of Obstetrics deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner Obstetrics opportunities
- Uncover companies actively partnering Obstetrics opportunities

Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Idiopathic Pulmonary Fibrosis Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Global Idiopathic Pulmonary Fibrosis Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • $ 6500
  • Industry report
  • February 2017
  • by P&S Market Research

Pipeline Overview Idiopathic pulmonary fibrosis (IPF) is referred to as progressive and chronic interstitial pneumonia without known cause. Pulmonary fibrosis is a disease in which tissue profound in lungs ...

Chronic Kidney Disease (CKD) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Chronic Kidney Disease (CKD) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • March 2017
  • by Transparency Market Research

Chronic Kidney Disease (CKD) Drugs Market (Drug Class - ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis - stimulating Agents (ESAs), and Diuretics; ...

Cholesterol Screening/ Cholesterol Lab Testing Services Market by Type of Customer, Geography & Qualitative Assessment - Forecasts to 2021

Cholesterol Screening/ Cholesterol Lab Testing Services Market by Type of Customer, Geography & Qualitative Assessment - Forecasts to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global cholesterol testing services market is expected to reach USD 17.5 billion by 2021 from USD 11.9 billion in 2016, growing at a CAGR of 8% during the forecast period. This market is segmented ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.